Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa
Public ClinicalTrials.gov record NCT00264615. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Pharmacokinetic (PK) study to characterize changes in serum concentrations in epilepsy patients when switching from LAMICTAL immediate-release to extended-release and vice versa.
Study identification
- NCT ID
- NCT00264615
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 45 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 13 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2005
- Primary completion
- May 31, 2006
- Completion
- May 31, 2006
- Last update posted
- Sep 22, 2016
2005 – 2006
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Anniston | Alabama | 36207 | — |
| GSK Investigational Site | Sun City | Arizona | 85351 | — |
| GSK Investigational Site | Lexington | Kentucky | 40503 | — |
| GSK Investigational Site | Lexington | Kentucky | 40536-0284 | — |
| GSK Investigational Site | Boston | Massachusetts | 02215 | — |
| GSK Investigational Site | Reno | Nevada | 89521 | — |
| GSK Investigational Site | New York | New York | 10016 | — |
| GSK Investigational Site | Toledo | Ohio | 43614-5809 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19140 | — |
| GSK Investigational Site | Nashville | Tennessee | 37232 | — |
| GSK Investigational Site | Dallas | Texas | 75230 | — |
| GSK Investigational Site | Richmond | Virginia | 23219 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Epilepsy trials
Other public records listing Epilepsy. Sorted by last update posted; newest first. Not a recommendation.
- NCT07768618: Electrophysiologic Mechanisms of Ketamine Antidepressant Response Not yet recruiting
- NCT07750496: Outcomes After Planned Discontinuation of AntiSeizure Medication Recruiting
- NCT07735715: HOBSCOTCH-YOUTH and Young Adults Not yet recruiting
- NCT06135285: A Device to Prevent Sudden Unexpected Death in Epilepsy: Detecting Peri-Ictal Body Position Not yet recruiting
- NCT05954182: Cognitive Enhancement Intervention for Creating a Healthy L.I.F.E (Lifestyle Interventions for Epilepsy) Active, not recruiting
- NCT04715646: A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00264615, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 22, 2016 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00264615 live on ClinicalTrials.gov.